Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on Human Epidermal Growth Factor 2 (Her2) Expression Changes in Human Breast Cancer After Radiotherapy

NCT01934478 is registered in ClinicalTrials.gov with Qingdao Central Hospital as lead sponsor.

NCT NCT01934478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01934478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on Human Epidermal Growth Factor 2 (Her2) Expression Changes in Human Breast Cancer After Radiotherapy
Lead sponsor
Qingdao Central Hospital
Phase
Observational
Overall status
Completed
Start date
August 31, 2013
Completion date
December 30, 2022
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human epidermal growth factor 2 negative carcinoma of breast